CLX stock sentiment todayThe Clorox Company
Sentiment verdict
Gossip first, financials second — COLD at 75% confidence.
Last updated · cached analysis, refreshes periodically
CLX
The Clorox CompanyClorox is struggling to regain margin momentum and market share following a devastating 2023 cyberattack, while trading at a premium valuation that the current growth profile doesn't justify.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for CLX. Not financial advice.
Price · last 12 months
Gossip
Market narrative is dominated by the long-tail recovery from the August 2023 cyberattack which crippled supply chains and led to significant shelf-space loss to private labels. Investors are skeptical about the pace of volume recovery in a cash-strapped consumer environment.
- ·Market share erosion to generic brands
- ·Supply chain normalization delays
- ·Post-pandemic 'normalization' of cleaning product demand
Financial
While the dividend remains a priority, fundamentals are stretched. Operating margins are recovering but remain below historical peaks, and the debt-to-EBITDA ratio has increased due to the operational disruptions of the past year.
- ·Forward P/E: ~22x (Premium to historical growth)
- ·Debt/Equity: High (>200%)
- ·Dividend Yield: ~3.8% (Attractive but payout ratio is high)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Quiet accumulation — the chatter is cold but the smart money is leaning in.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Continued consumer trade-down to private label bleach and wipes
- ·Inability to pass through further price increases without losing volume
- ·High interest expense impacting net income
Peer temperature
How direct competitors stack up against CLX right now.
- HOTPGProcter & Gamble
HOTTER — Superior pricing power and a more diversified brand portfolio provide a safer moat with better free cash flow conversion.
See full analysis → - NEUTRALCHDChurch & Dwight
WARMER — Maintaining stronger organic volume growth through value-positioned brands like Arm & Hammer while avoiding Clorox's recent operational volatility.
See full analysis → - NEUTRALKMBKimberly-Clark
STEADIER — Trading at a more attractive valuation (18x forward P/E) with more consistent execution in the personal care segment compared to Clorox's recovery play.
See full analysis →
- CLX+8.6%
- PG+11.2%
- CHD+13.8%
- KMB+10.8%
Analyst price target
Consensus average of 13 analysts · median 90.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.